Optimizing asparaginase therapy for acute lymphoblastic leukemia

Current Opinion in Oncology

Volumn 25, Issue SUPPL.1, 2013, Pages

  Rizzari, Carmelo ^a   Conter, Valentino ^a   Starý, Jan ^b   Colombini, Antonella ^a   Moericke, Anja ^c   Schrappe, Martin ^c  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

acute lymphoblastic leukemia; asparaginase; childhood; hypersensitivity; silent inactivation

Indexed keywords

ASPARAGINASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CLINICAL PROTOCOL; CROSS REACTION; DISEASE FREE SURVIVAL; DNA SYNTHESIS; DRUG ACTIVITY; DRUG HALF LIFE; ENZYME REPLACEMENT; ESCHERICHIA COLI; EVENT FREE SURVIVAL; HUMAN; IMMUNOGENICITY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; RNA SYNTHESIS; TREATMENT DURATION; TREATMENT INDICATION;

ASPARAGINASE; DRUG HYPERSENSITIVITY; ESCHERICHIA COLI; HUMANS; PECTOBACTERIUM CHRYSANTHEMI; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84873347776     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835d7d85     Document Type: Review

References (36)

1. Müller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998; 28:97-113.
2. Pieters R, Hunger S, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia. Cancer 2011; 117:238-249.
3. Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993; 11:1780-1786.
4. Vieira Pinheiro JP, Ahlke E, Nowak-Göttl U, et al. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol 1999; 104:313-320.
5. Klug Albertsen B, Schrøder H, Jakobsen P, et al. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clin Pharmacol 2001; 52:433-437.
6. Avramis VI, Martin-Aragon S, Avramis EV, et al. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of Erwinase population PK-PD models. Anticancer Res 2007; 27 (4C):2561-2572.
7. Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996; 32A:1544-1550.
8. Asselin BL, Lorenson MY,Whitin JC, et al. Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor. Cancer Res 1991; 51:6568-6573.
9. Ertel IJ, Nesbit ME, Hammond D, et al. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group. Cancer Res 1979; 39:3893-3896.
10. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97:1211-1218.
11. Ogawa C, Ohara A, Manabe A, et al. Tokyo Children's Cancer Study Group (TCCSG) Study L99-15 [abstract]. Blood 2005; 106:abstract 878.
12. Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23:7161-7167.
13. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 1999; 13:335-342.
14. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109:896-904.
15. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coliasparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 2002; 99:2734-2739.
16. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002; 99:1986-1994.
17. Zalewska-Szewczyk B, Andrzejewski W, Mlynarski W, et al. The antiasparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma 2007; 48:931-936.
18. Panosyan EH, Seibel NL, Martin-Aragon S; for the Children's Cancer Group Study CCG-1961. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004; 26: 217-226.
19. Wetzler M, Sanford BL, Kurtzberg J, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood 2007; 109:4164-4167.
20. Woo MH, Hak LJ, Storm MC, et al. Antiasparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998; 12:1527-1533.
21. Avramis VI, Tiwari PN. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomed 2006; 1:241-254.
22. Raetz EA, Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Oncol 2010; 32:554-563.
23. Common terminology criteria for adverse events v3.0 available at: http://ctep. cancer.gov/protocoldevelopment/electronic-applications/docs/ ctcaev3.pdf
24. Medical Research Council Working Party on Leukaemia in Children. UK National Acute Lymphoblastic Leukaemia (ALL) trial (UKALL 2003). Available at https://www.ctsu.ox.ac.uk/research/mega-trials/leukaemia-trials/ukall-2003/ protocol-version-7
25. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Acute lymphoblastic leukemia. Available at http://www.nccn. org/professionals/physician-gls/f-guidelines.asp
26. Hawkins DS, Park JR, Thomson BG, et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res 2004; 10:5335-5341.
27. Albertsen BK, Schrøder H, Jakobsen P, et al. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol 2002; 38:310-316.
28. Klug Albertsen B, Schmiegelow K, Schrøder H, et al. Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study. Cancer Chemother Pharmacol 2002; 50:117-120.
29. Vrooman LM, Supko JG, Neuberg DS, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2010; 54:199-205.
30. Willer A, Gerss J, König T, et al. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials. Blood 2011; 118:5774-5782.
31. Wang B, Relling MV, Storm MC, et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 2003; 17:1583-1588.
32. Zalewska-Szewczyk B, Gach A, Wyka K, et al. The cross-reactivity of antiasparaginase antibodies against different L-asparaginase preparations. Clin Exp Med 2009; 9:113-116.
33. Asselin B. The three asparaginases: comparative pharmacology and optimal use in childhood leukemia. In: Kaspers et al., editors. Drug resistance in leukemia and lymphoma III. Kluwer Academic/Plenum Publishers; 1999. pp. 621-629.
34. Schrey D, Speitel K, Lanvers-Kaminsky C, et al. Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial. Pediatr Blood Cancer 2011; 57:378-384.
35. Schrey D, Borghorst S, Lanvers-Kaminsky C, et al. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007. Pediatr Blood Cancer 2010; 54:952-958.
36. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115:3206-3214.